| Ulcerative Colitis
Simponi vs Yusimry
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Simponi vs Yusimry with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYusimry has a higher rate of injection site reactions vs Simponi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yusimry but not Simponi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Simponi
Yusimry
At A Glance
SC injection
Every 4 weeks
TNF-alpha inhibitor
SC injection
Every 1-2 weeks
TNF-alpha inhibitor
Indications
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Ulcerative Colitis
- Rheumatoid Arthritis
- Juvenile arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 50 mg SC once a month.
Ulcerative Colitis (adults and pediatric patients >=40 kg) 200 mg SC at Week 0, 100 mg at Week 2, then 100 mg every 4 weeks.
Ulcerative Colitis (pediatric patients >=15 kg to <40 kg) 100 mg SC at Week 0, 50 mg at Week 2, then 50 mg every 4 weeks.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; in Rheumatoid Arthritis without concomitant MTX, may increase to 40 mg every week or 80 mg every other week.
Juvenile arthritis 40 mg SC every other week for patients 2 years of age and older weighing 30 kg or greater.
Crohn Disease, Ulcerative Colitis 160 mg SC on Day 1 (or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29.
Psoriasis vulgaris, Uveitis Initial 80 mg SC, then 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1 (or split over two consecutive days), 80 mg on Day 15, then 40 mg weekly or 80 mg every other week starting Day 29.
Contraindications
—
—
Adverse Reactions
Most common (>=1%) Upper respiratory tract infection, viral infections, bronchitis, superficial fungal infections, sinusitis, injection site reaction, alanine aminotransferase increased, aspartate aminotransferase increased, hypertension, dizziness, paresthesia, constipation
Serious Serious infections, malignancies, congestive heart failure, demyelinating disorders, hepatitis B reactivation, autoimmunity, hematologic cytopenias, hypersensitivity reactions
Postmarketing Serious systemic hypersensitivity reactions, sarcoidosis, melanoma, Merkel cell carcinoma, interstitial lung disease, skin exfoliation, lichenoid reactions, rash, bullous skin reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, sinusitis, headache, rash, nausea, abdominal pain, back pain, urinary tract infection, hyperlipidemia, hypercholesterolemia, accidental injury.
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity, liver enzyme elevations.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, systemic vasculitis, deep vein thrombosis.
Pharmacology
Golimumab is a human IgG1 monoclonal antibody (TNF-alpha inhibitor) that binds to both the soluble and transmembrane bioactive forms of human TNF-alpha, preventing its binding to receptors and inhibiting the biological activity of TNF-alpha in inflammatory diseases.
TNF-alpha antagonist; adalimumab-aqvh is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Simponi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Yusimry
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Simponi
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (7/8) · Qty limit (7/8)
Yusimry
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Simponi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Yusimry
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Simponi.
No savings programs available for Yusimry.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SimponiView full Simponi profile
YusimryView full Yusimry profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.